Biopure To Develop Hemopure As Cardioprotective Agent Under Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has established a cardiology medical advisory board under the direction of new CEO Zafiris Zafirelis. Biopure expects that data from FDA-requested animal studies will allow it to move forward with U.S. clinical trials for cardiac ischemia.